Lm-LLO-TT + Gemcitabine for Pancreatic Cancer

This trial tests a new treatment for pancreatic cancer that cannot be surgically removed or has metastasized. The study aims to determine the safest dose of a new immunotherapy, Lm-LLO-TT, used with a low-dose chemotherapy drug, gemcitabine. Individuals who have previously received treatment for pancreatic cancer but still have measurable disease may be suitable candidates for this trial. The goal is to identify the optimal dose for future studies and assess any side effects. Researchers will closely monitor participants for safety and the treatment's effectiveness against cancer. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

A previous study tested the immunotherapy Lm-LLO-TT to determine its safety for humans. This treatment uses a weakened form of bacteria designed to fight cancer by targeting specific proteins. The study assessed how well participants tolerated the treatment and whether any major side effects occurred.

Initial results suggested that Lm-LLO-TT was generally well-tolerated. However, some participants experienced mild to moderate side effects, such as fever or tiredness, which are common with treatments that boost the immune system. As this is an early-stage trial, the main goal is to find the safest dose. Researchers continue to collect safety data and closely monitor for any adverse reactions.

Gemcitabine, used alongside Lm-LLO-TT, is already an approved cancer treatment. Its side effects, such as nausea or low blood counts, are well-known to researchers.

Most treatments for pancreatic cancer, like Gemcitabine, attack rapidly dividing cancer cells. But Lm-LLO-TT works differently. It uses a live-attenuated bacterium to stimulate the immune system, training it to target and destroy pancreatic cancer cells. This unique approach not only offers a potential new way to fight the disease but also leverages the body's natural defenses, which is why researchers are excited about its possibilities.

Research has shown that Lm-LLO-TT may help treat pancreatic cancer. In studies with mice, it significantly reduced tumor size and spread, improving survival rates by 40% compared to untreated subjects. In human trials, combining Lm-LLO-TT with chemotherapy resulted in 84.6% of patients experiencing disease control, with tumors either stabilizing or shrinking. These findings suggest that Lm-LLO-TT could help manage pancreatic cancer, but further research is needed to confirm its effectiveness in people.⁶⁷⁸⁹¹⁰